Phase I Study of RiMO-401 With Radiation in Advanced Tumors

Description

This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.

Conditions

Advanced Solid Tumor, Intratumoral Injection

Study Overview

Study Details

Study overview

This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.

Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced Tumors

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Illinois at Chicago, Chicago, Illinois, United States, 60612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of advanced or metastatic cancer not amenable to curative therapy
  • * Lesion that is amenable to palliative radiotherapy
  • * Lesion that is technically feasible for intratumoral injection
  • * Target tumor in region not in the field that was irradiated within the past six months
  • * Patients with advanced or metastatic HNSCC must have progressed on or been intolerant to standard of care therapies including platinum-based chemotherapy and anti-PD(L)1 therapy, prior to study enrollment
  • * Patient must have recovered from acute toxic effects (≤ grade 1) of previous cancer treatments prior to enrollment
  • * Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion
  • * ECOG score of 0-1
  • * Have a life expectancy of at least 12 weeks
  • * Have adequate bone marrow reserve and adequate liver function
  • * Both males and females and their partners of childbearing potential must agree to use adequate contraceptive measures
  • * Patients must sign a study-specific informed consent form prior to study entry
  • * Age 18 years or older.
  • * Patients with a histological diagnosis of lymphomas and/or leukemias
  • * Patients with significant blood vessels (such as carotid artery encasement) or other major structures in the tumor region to be injected
  • * Patients may not have received chemotherapy, targeted therapies, immunotherapies, biologic response modifiers and/or hormonal therapy within the last 14 days
  • * Ongoing clinically significant infection at or near the incident lesion
  • * Major surgery over the target area (excluding placement of vascular access) \<21 days from beginning of the study drug or minor surgical procedures \<7 days
  • * Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
  • * Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial
  • * Pregnant and nursing women
  • * Patients with a target lesion located in a previously irradiated field
  • * Patients with a target lesion in the field that had complications from prior radiotherapy that are not amenable to repeat irradiation.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Coordination Pharmaceuticals, Inc.,

Study Record Dates

2026-07